CD44 and central nervous system cancer: Additionally, biomarkers associated with glioma progression (TP53, EGFR, and FERMT1) and glioma stem cells (CD44, S100A4, and SOX2) were examined across different spatial regions of both Glio-IDH-wt and Glio-IDH-mut (Figure 2D).